Ejrnaes Mette, von Herrath Matthias G, Christen Urs
Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA.
Clin Dev Immunol. 2006 Jun-Dec;13(2-4):337-47. doi: 10.1080/17402520600800721.
The use of neutralizing antibodies is one of the most successful methods to interfere with receptor-ligand interactions in vivo. In particular blockade of soluble inflammatory mediators or their corresponding cellular receptors was proven an effective way to regulate inflammation and/or prevent its negative consequences. However, one problem that comes along with an effective neutralization of inflammatory mediators is the general systemic immunomodulatory effect. It is therefore important to design a treatment regimen in a way to strike at the right place and at the right time in order to achieve maximal effects with minimal duration of immunosuppression or hyperactivation. In this review we reflect on two examples of how short time administration of such neutralizing antibodies can block two distinct inflammatory consequences of viral infection. First, we review recent findings that blockade of IL-10/IL-10R interaction can resolve chronic viral infection and second, we reflect on how neutralization of the chemokine CXCL10 can abrogate virus-induced type 1 diabetes.
使用中和抗体是体内干扰受体-配体相互作用最成功的方法之一。特别是,阻断可溶性炎症介质或其相应的细胞受体已被证明是调节炎症和/或预防其负面后果的有效方法。然而,有效中和炎症介质所带来的一个问题是普遍的全身免疫调节作用。因此,以在正确的时间和地点发挥作用的方式设计治疗方案很重要,以便在最短的免疫抑制或过度激活持续时间内实现最大效果。在本综述中,我们思考了两个例子,即短时间施用此类中和抗体如何能够阻断病毒感染的两种不同炎症后果。首先,我们回顾了最近的研究发现,即阻断IL-10/IL-10R相互作用可以解决慢性病毒感染;其次,我们思考了趋化因子CXCL10的中和如何能够消除病毒诱导的1型糖尿病。